MCA logo



Cabozantinib, Ipilimumab and Nivolumab Combination for untreated advanced renal-cell carcinoma 

Combination of Ipilimumab and Nivolumab is one of the first line treatment recommended in patients with advanced renal-cell carcinoma with intermediate or poor prognostic risk according to International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) categories[1]. However, in the CheckMate 214 trial [2], which studied nivolumab plus ipilimumab . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: